Press release

Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease, has just unveiled data from a clinical trial of its lead candidate, UDP-003, at the American Heart Association Vascular Discovery Scientific Sessions. Data from a study...

We are super excited to share with you that today we released AI4L - "AI for Practical Longevity", an open-source system that enables anyone to produce rigorous, evidence-based reviews of health and longevity interventions using frontier AI models. Our novel "Audit-Driven Prompting" method enables iterative self-auditing and eliminates hallucinations with live citation verification and zero-tolerance...

Longevity Day at NFC Summit Lisbon has announced its confirmed speaker lineup ahead of its debut on 4 June 2026 at the Unicorn Factory in Lisbon. The event will bring together scientists, clinicians, founders, and investors from across the longevity ecosystem for a full-day program spanning ancestral wisdom, cutting-edge science, and frontier biotech. The event...

BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today reported results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a...

The Asia-Pacific Longevity Medicine Society (APLMS), in partnership with The Kitalys Institute, announced that the 2026 Asia-Pacific Healthy Longevity International Summit (APAC-LMIS) will be held in Hong Kong from October 1–4, 2026, at the Hopewell Hotel. The Summit is expected to bring together more than 2,000 global leaders across longevity medicine, geroscience, pharmas, digital health, artificial...

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the...